All In Biotech

Drug Trial Radar · NCT00133692

INVEST: INternational VErapamil SR Trandolapril STudy

INternational VErapamil SR Trandolapril STudy

Last checked: Nov 19, 2026Latest source record: Sep 20, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 22,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

22,000

Actual

Start

Sep 1997

Primary completion

Not stated

Study completion Feb 2003

Sponsor

Lead sponsor
University of FloridaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Abbott
First posted
Aug 23, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Because blood pressure affects the heart, blood vessels, kidneys, and the entire body, it is important to keep it as normal as possible. There are several different ways to control blood pressure and to prevent or limit the development of heart disease due to high blood pressure. The purpose of this study is to compare two treatments to see how well they work and the difference in their side effects. One treatment includes the use of a calcium antagonist drug (Isoptin sustained release \[SR\] or Verapamil SR). The other treatment excludes the calcium antagonist and may include a non-calcium antagonist drug called a beta blocker (Tenormin or Atenolol). Both treatments may also include medication called angiotensin converting enzyme (ACE) inhibitors and water pills. None of the drugs in this study are experimental, they are all approved by the Food and Drug Administration (FDA).

Conditions

  • Hypertension
  • Coronary Artery Disease

Interventions

  • Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ)Drug

  • Atenolol/HCTZ/TrandolaprilDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. First occurrence of death or nonfatal myocardial infarction (MI) or nonfatal stroke

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Florida

    Gainesville, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.